186 related articles for article (PubMed ID: 36910721)
41. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
42. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
43. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
44. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
45. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
ElBayoumi TA; Torchilin VP
Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
[TBL] [Abstract][Full Text] [Related]
46. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
48. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin.
Jiang SP; He SN; Li YL; Feng DL; Lu XY; Du YZ; Yu HY; Hu FQ; Yuan H
Int J Nanomedicine; 2013; 8():3141-50. PubMed ID: 23990722
[TBL] [Abstract][Full Text] [Related]
49. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
[TBL] [Abstract][Full Text] [Related]
50. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
Chen Z; Deng J; Zhao Y; Tao T
Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
[TBL] [Abstract][Full Text] [Related]
51. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
[TBL] [Abstract][Full Text] [Related]
52. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670
[TBL] [Abstract][Full Text] [Related]
53. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
54. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
55. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration.
Kuai R; Yuan W; Li W; Qin Y; Tang J; Yuan M; Fu L; Ran R; Zhang Z; He Q
Mol Pharm; 2011 Dec; 8(6):2151-61. PubMed ID: 21981683
[TBL] [Abstract][Full Text] [Related]
56. Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment.
Deng B; Ma B; Ma Y; Cao P; Leng X; Huang P; Zhao Y; Ji T; Lu X; Liu L
J Nanobiotechnology; 2022 Mar; 20(1):140. PubMed ID: 35303868
[TBL] [Abstract][Full Text] [Related]
57. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; CichoĊ T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
58. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
[TBL] [Abstract][Full Text] [Related]
59. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
60. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]